<?xml version='1.0' encoding='utf-8'?>
<document id="10660641"><sentence text="Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus."><entity charOffset="6-18" id="DDI-PubMed.10660641.s1.e0" text="itraconazole" /><entity charOffset="23-42" id="DDI-PubMed.10660641.s1.e1" text="hydroxyitraconazole" /><entity charOffset="79-86" id="DDI-PubMed.10660641.s1.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10660641.s1.e0" e2="DDI-PubMed.10660641.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s1.e0" e2="DDI-PubMed.10660641.s1.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s1.e0" e2="DDI-PubMed.10660641.s1.e2" /><pair ddi="false" e1="DDI-PubMed.10660641.s1.e1" e2="DDI-PubMed.10660641.s1.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s1.e1" e2="DDI-PubMed.10660641.s1.e2" /></sentence><sentence text="A patient treated with itraconazole (ITCZ) under the diagnosis of Aspergillus flavus-induced chronic hypertrophic pachymeningitis is presented"><entity charOffset="23-35" id="DDI-PubMed.10660641.s2.e0" text="itraconazole" /><entity charOffset="37-41" id="DDI-PubMed.10660641.s2.e1" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.10660641.s2.e0" e2="DDI-PubMed.10660641.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s2.e0" e2="DDI-PubMed.10660641.s2.e1" /></sentence><sentence text=" The reason for the successful cure of this patient was investigated by the pharmacokinetic analysis of serum levels of ITCZ"><entity charOffset="120-123" id="DDI-PubMed.10660641.s3.e0" text="ITCZ" /></sentence><sentence text=" Concurrently administered digoxin was also investigated for its drug-drug interaction"><entity charOffset="27-34" id="DDI-PubMed.10660641.s4.e0" text="digoxin" /></sentence><sentence text=" The patient (a 75-year-old male) developed ophthalmopathy, and was diagnosed as having A" /><sentence text=" flavus hypertrophic pachymeningitis by pachymeninx biopsy" /><sentence text=" After admission, he was treated with FLCZ, AMPH, 5-FC and MCZ"><entity charOffset="38-42" id="DDI-PubMed.10660641.s7.e0" text="FLCZ" /><entity charOffset="44-48" id="DDI-PubMed.10660641.s7.e1" text="AMPH" /><entity charOffset="50-54" id="DDI-PubMed.10660641.s7.e2" text="5-FC" /><pair ddi="false" e1="DDI-PubMed.10660641.s7.e0" e2="DDI-PubMed.10660641.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s7.e0" e2="DDI-PubMed.10660641.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s7.e0" e2="DDI-PubMed.10660641.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10660641.s7.e1" e2="DDI-PubMed.10660641.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s7.e1" e2="DDI-PubMed.10660641.s7.e2" /></sentence><sentence text=" The infection tended to subside with the AMPH administration"><entity charOffset="42-45" id="DDI-PubMed.10660641.s8.e0" text="AMPH" /></sentence><sentence text=" Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective, daily administration of 200 mg of ITCZ was initiated, and the inflammatory signs and symptoms gradually subsided"><entity charOffset="130-133" id="DDI-PubMed.10660641.s9.e0" text="ITCZ" /><entity charOffset="42-45" id="DDI-PubMed.10660641.s9.e1" text="AMPH" /><pair ddi="false" e1="DDI-PubMed.10660641.s9.e1" e2="DDI-PubMed.10660641.s9.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s9.e1" e2="DDI-PubMed.10660641.s9.e0" /></sentence><sentence text=" The symptoms did not recur during the 36 months of itraconazole treatment after discharge, and it was concluded that ITCZ was effective for A"><entity charOffset="52-64" id="DDI-PubMed.10660641.s10.e0" text="itraconazole" /><entity charOffset="118-129" id="DDI-PubMed.10660641.s10.e1" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.10660641.s10.e0" e2="DDI-PubMed.10660641.s10.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s10.e0" e2="DDI-PubMed.10660641.s10.e1" /></sentence><sentence text=" flavus hypertrophic pachymeningitis" /><sentence text=" Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93"><entity charOffset="40-47" id="DDI-PubMed.10660641.s12.e0" text="OH-ITCZ" /><entity charOffset="31-37" id="DDI-PubMed.10660641.s12.e1" text="ITCZ" /><entity charOffset="43-49" id="DDI-PubMed.10660641.s12.e2" text="ITCZ" /><entity charOffset="60-66" id="DDI-PubMed.10660641.s12.e3" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e1" e2="DDI-PubMed.10660641.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e1" e2="DDI-PubMed.10660641.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e1" e2="DDI-PubMed.10660641.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e1" e2="DDI-PubMed.10660641.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e0" e2="DDI-PubMed.10660641.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e0" e2="DDI-PubMed.10660641.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e0" e2="DDI-PubMed.10660641.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e2" e2="DDI-PubMed.10660641.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10660641.s12.e2" e2="DDI-PubMed.10660641.s12.e3" /></sentence><sentence text="2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng" /><sentence text="h/ml, OH-ITCZ: Cmax 159"><entity charOffset="9-12" id="DDI-PubMed.10660641.s14.e0" text="ITCZ" /></sentence><sentence text="4 ng/ml, T1/2 beta 16" /><sentence text=" 2 hours, AUC0-24 of 1391 ng" /><sentence text="h/ml" /><sentence text=" Both ITCZ and OH-ITCZ reached steady states seven days after administration began"><entity charOffset="6-9" id="DDI-PubMed.10660641.s18.e0" text="ITCZ" /><entity charOffset="18-21" id="DDI-PubMed.10660641.s18.e1" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.10660641.s18.e0" e2="DDI-PubMed.10660641.s18.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s18.e0" e2="DDI-PubMed.10660641.s18.e1" /></sentence><sentence text=" The ITCZ and OH-ITCZ levels in serum collected 36 months after the initiation of administration were 452"><entity charOffset="14-21" id="DDI-PubMed.10660641.s19.e0" text="OH-ITCZ" /><entity charOffset="5-11" id="DDI-PubMed.10660641.s19.e1" text="ITCZ" /><entity charOffset="17-23" id="DDI-PubMed.10660641.s19.e2" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.10660641.s19.e1" e2="DDI-PubMed.10660641.s19.e1" /><pair ddi="false" e1="DDI-PubMed.10660641.s19.e1" e2="DDI-PubMed.10660641.s19.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s19.e1" e2="DDI-PubMed.10660641.s19.e2" /><pair ddi="false" e1="DDI-PubMed.10660641.s19.e0" e2="DDI-PubMed.10660641.s19.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s19.e0" e2="DDI-PubMed.10660641.s19.e2" /></sentence><sentence text="9 ng/ml and 1233" /><sentence text="6 ng/ml, respectively" /><sentence text=" Cmax and AUC0-24 of ITCZ and OH-ITCZ on the second day were markedly lower than those in healthy adults reported by Oguchi et al"><entity charOffset="21-24" id="DDI-PubMed.10660641.s22.e0" text="ITCZ" /><entity charOffset="33-36" id="DDI-PubMed.10660641.s22.e1" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.10660641.s22.e0" e2="DDI-PubMed.10660641.s22.e0" /><pair ddi="false" e1="DDI-PubMed.10660641.s22.e0" e2="DDI-PubMed.10660641.s22.e1" /></sentence><sentence text=", and hypoalbuminemia observed at administration on that day was considered the most probable cause" /><sentence text=" It was assumed that the most plausible reason for a successful cure even at a low dose of ITCZ was the increase of distribution to tissue by the increase of the unbound form"><entity charOffset="91-94" id="DDI-PubMed.10660641.s24.e0" text="ITCZ" /></sentence><sentence text=" Digoxin was concurrently given to this patient at 0"><entity charOffset="1-8" id="DDI-PubMed.10660641.s25.e0" text="Digoxin" /></sentence><sentence text=" 125 mg/day, but the blood digoxin level was not elevated"><entity charOffset="27-34" id="DDI-PubMed.10660641.s26.e0" text="digoxin" /></sentence><sentence text=" Consideration of the blood level of albumin is believed to be important for evaluating the blood concentration of ITCZ"><entity charOffset="115-121" id="DDI-PubMed.10660641.s27.e0" text="ITCZ" /></sentence><sentence text="" /></document>